Arzerra

Treatment for Chronic Lymphocytic Leukemia

Update: Arzerra (ofatumumab) Now FDA Approved - October 26, 2009

FDA Extends Review of Arzerra

FDA Extends Review of Arzerra (ofatumumab)

LONDON, June 16, 2009--GlaxoSmithKline and Genmab A/S today announced that the United States Food and Drug Administration (FDA) informed the companies that the agency has extended the action date for the ofatumumab BLA application by three months.

The BLA was submitted on 30 January 2009 and was granted priority review by the FDA.  Under priority review, the FDA sets the target date for a decision at six months, rather than the standard 10 month review.  The three month extension will allow the agency to review additional chemistry and manufacturing data submitted on 5 June. The new action date for the BLA is 31 October 2009.

An FDA Oncology Drugs Advisory Committee (ODAC) held on 29 May 2009, voted 10-3 that ofatumumab was likely to offer clinical benefit for certain patients with chronic lymphocytic leukaemia (CLL).  Data from the pivotal trial of ofatumumab were presented at the American Society of Hematology 2008 annual meeting and at the American Society of Clinical Oncology 2009 annual meeting.

CLL is the most common adult leukaemia and one of the most common malignant lymphoid diseases. In the United States, about 90,000 people are living with CLL, with approximately 15,000 estimated new cases being diagnosed in 2009.

GSK and Genmab are committed to working with the FDA in order to bring this potential new treatment option to patients. 

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at www.gsk.com.

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.  Genmab’s world class discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options.  For more information on Genmab’s products and technology, visit www.genmab.com.
Enquiries:
UK Media enquiries:
 Philip Thomson
 (020) 8047 5502
 David Outhwaite
 (020) 8047 5502
 Stephen Rea
 (020) 8047 5502
US Media enquiries:
 Nancy Pekarek
 (919) 483 2839
 Mary Anne Rhyne
 (919) 483 2839
 Kevin Colgan
 (919) 483 2839
 Lisa Behrens
 (919) 483 2839
European Analyst/Investor enquiries:
 David Mawdsley
 (020) 8047 5564
 Sally Ferguson
 (020) 8047 5543
 Gary Davies
 (020) 8047 5503
US Analyst/ Investor enquiries:
 Tom Curry
 (215) 751 5419
 Jen Hill Baxter
 (215) 751 7002
 

Posted: June 2009

Related Articles

Arzerra (ofatumumab) FDA Approval History

View comments

Hide
(web2)